Skip to main content

Table 3 Key indicators of W. bancrofti in human population over the study period.

From: The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda

 

2007

2010

Number of individuals providing blood samples

896

1304

Number of blood samples from < 5 yrs (%)

348 (38.9)

521 (40.0)

Crude % prevalence estimates 1

  

   W. bancrofti antigen in < 5 years

-

0.2 (0.01-1.1)

   W. bancrofti antigen in ≥ 5 years

-

6.0 (4.4-7.9)

   W. bancrofti mf in < 5 years2

0.9 (0.2-2.5)

0.0 (0.0-0.7)3

   W. bancrofti mf in ≥ 5 years2

6.8 (4.8-9.3)

0.8 (0.3-1.7)

   W. bancrofti geometric mean (range)

165 (10-3,790)

80 (10-260)

   Lymphoedema/elephantiasis

1.2 (0.6-2.2)

-

   Hydrocoele, amongst males

1.5 (0.6-3.3)

-

   Acute adenolymphangitis

1.2 (0.6-2.2)

-

Adjusted % prevalence estimates 4

  

   W. bancrofti antigen

-

2.1 (1.2-3.7)

   W. bancrofti mf

3.7 (2.6-5.3)

0.4 (0.2-1.0)

  1. 1 With exact binomial 95% confidence interval
  2. 2 All ICT negative samples assumed to be mf negative
  3. 3 One-sided test, 97.5 confidence interval
  4. 4 Estimated using generalised linear models, with robust 95% confidence intervals. All models are also adjusted for sex. Age was included as a linear variable in W. bancrofti mf 2007 and 2010 models. Age was included as a categorical variable with 10 year bins and grouping all ≥ 50 years in W. bancrofti antigen 2010 model.